Delta-Omicron recombinant escapes therapeutic antibody neutralization

The emergence of recombinant viruses is a threat to public health, as recombination may integrate variant-specific features that together result in escape from treatment or immunity. The selective advantages of recombinant SARS-CoV-2 isolates over their parental lineages remain unknown. We identifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Duerr, Ralf, Zhou, Hao, Tada, Takuya, Dimartino, Dacia, Marier, Christian, Zappile, Paul, Wang, Guiqing, Plitnick, Jonathan, Griesemer, Sara B., Girardin, Roxanne, Machowski, Jessica, Bialosuknia, Sean, Lasek-Nesselquist, Erica, Hong, Samuel L., Baele, Guy, Dittmann, Meike, Ortigoza, Mila B., Prasad, Prithiv J., McDonough, Kathleen, Landau, Nathaniel R., St George, Kirsten, Heguy, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937133/
https://www.ncbi.nlm.nih.gov/pubmed/36844451
http://dx.doi.org/10.1016/j.isci.2023.106075
Descripción
Sumario:The emergence of recombinant viruses is a threat to public health, as recombination may integrate variant-specific features that together result in escape from treatment or immunity. The selective advantages of recombinant SARS-CoV-2 isolates over their parental lineages remain unknown. We identified a Delta-Omicron (AY.45-BA.1) recombinant in an immunosuppressed transplant recipient treated with monoclonal antibody Sotrovimab. The single recombination breakpoint is located in the spike N-terminal domain adjacent to the Sotrovimab binding site. While Delta and BA.1 are sensitive to Sotrovimab neutralization, the Delta-Omicron recombinant is highly resistant. To our knowledge, this is the first described instance of recombination between circulating SARS-CoV-2 variants as a functional mechanism of resistance to treatment and immune escape.

Ejemplares similares